Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 28;11:2158. doi: 10.3389/fimmu.2020.02158

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Fiorcari, Maffei, Vallerini, Scarfò, Barozzi, Maccaferri, Potenza, Ghia, Luppi and Marasca.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Circulating CD14+ monocytes are altered during ibrutinib treatment in CLL patients. Blood samples isolated from CLL patients pre-treatment and after 3 month of treatment with ibrutinib were analyzed. (A) Diagram shows the viability of CD14+ monocyte population. Ibrutinib did not affect the survival of monocytic population (n = 14, P = ns). (B) Secretion of TNF-α was measured in 12 CLL patients. Diagram shows a significant reduction of TNF-α levels after 3 months of treatment with ibrutinib (n = 12, *P < 0.05). (C) The phagocytic activity was measured in 13 CLL samples. Bar diagram shows the percentage of increase or reduction in phagocytic activity after 3 months of treatment with ibrutinib compared with pre-treated sample for each patient (n = 13, *P < 0.05).